Approval · Notice of Compliance 30743 · 2023
PMS-OXYCODONE: Notice of Compliance 30743
Issued May 15, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30743
- Date
- May 15, 2023
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph and Package Insert
- Canadian reference product
- OXY.IR (Purdue Pharma)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-OXYCODONE | Not yet assigned | — |
Medicinal ingredients
- OXYCODONE HYDROCHLORIDE 5 MG per TAB
- OXYCODONE HYDROCHLORIDE 10 MG per TAB
- OXYCODONE HYDROCHLORIDE 20 MG per TAB